<DOC>
	<DOCNO>NCT01584440</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability efficacy AVP-923 compare placebo , treatment symptom agitation patient Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Study AVP-923 ( Dextromethorphan/Quinidine ) Treatment Symptoms Agitation Alzheimer 's Patients</brief_title>
	<detailed_description>Eligible patient study must diagnosis probable AD must clinically meaningful agitation secondary AD . This multicenter , randomize , double-dummy , double-blind , placebo-controlled study , consist 10 week treatment . Up 200 patient enrol approximately 30-40 center US . Study medication administer orally twice-daily Day 1 Day 70 . Screening must occur within within approximately 4 week prior randomization . Following screening procedure assessment inclusion exclusion criterion , eligible patient randomize study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Key Diagnosis probable Alzheimer 's disease ( AD ) . The patient clinically significant symptom agitation secondary AD , interfere daily routine prescription medication deem indicated , opinion investigator . Either outpatients resident assistedliving facility skilled nursing home . CGIS score â‰¥ 4 ( moderately ill ) screen baseline . Mini Mental State Examination ( MMSE ) score screen 8 28 ( inclusive ) . Caregiver able willing comply require study procedure , ensure patient attends study visit take study medication instruct . In order qualify caregiver study , individual spend time patient minimum 4 hour 4 separate day per week . Key Patient type dementia ( e.g. , vascular dementia , frontotemporal dementia , Parkinson 's disease , substanceinduced dementia ) . Patients coexistent clinically significant unstable systemic disease could confound interpretation safety result study ( e.g . malignancy , poorly control diabetes , poorly control hypertension , unstable pulmonary , renal hepatic disease , unstable ischemic cardiac disease , dilate cardiomyopathy , certain cardiac conduction abnormality include QTc prolongation , unstable valvular heart disease ) . Patients myasthenia gravis .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>